Table 1.
Definition of outcome measures.
Figure 1.
PRISMA flow diagram.
Table 2.
Individual study.
Figure 2.
Risk of bias summary: review authors' judgments about each risk of bias item for each included study.
Table 3.
Summary of studies.
Table 4.
Summary of adverse events and discontinuation.
Table 5.
GRADE Analysis: quality assessment of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia.
Figure 3.
Adjunctive aripiprazole vs. placebo for antipsychotic-induced hyperprolactinemia: forest plot for insomnia, headache, sedation, and psychiatric disorder.
Figure 4.
Adjunctive aripiprazole vs. placebo for antipsychotic-induced hyperprolactinemia: forest plot for a secondary analysis of insomnia, headache, sedation and forest plot for extrapyramidal symptoms, dry mouth, and fatigue.
Figure 5.
Adjunctive aripiprazole vs. placebo for antipsychotic-induced hyperprolactinemia: forest plot for prolactin level normalization.
Figure 6.
Adjunctive aripiprazole vs. placebo for antipsychotic-induced hyperprolactinemia: forest plot for discontinuation.